Kennedy Capital Management LLC Has $1.30 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Kennedy Capital Management LLC lowered its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 45.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,260 shares of the company’s stock after selling 72,751 shares during the period. Kennedy Capital Management LLC owned 0.18% of Nurix Therapeutics worth $1,297,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its position in Nurix Therapeutics by 351.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after buying an additional 4,367 shares during the last quarter. Quest Partners LLC bought a new position in shares of Nurix Therapeutics in the 4th quarter valued at approximately $59,000. EntryPoint Capital LLC bought a new stake in Nurix Therapeutics during the first quarter worth approximately $123,000. Jump Financial LLC acquired a new stake in shares of Nurix Therapeutics in the fourth quarter worth $158,000. Finally, New York State Common Retirement Fund boosted its holdings in shares of Nurix Therapeutics by 59.5% during the 4th quarter. New York State Common Retirement Fund now owns 16,156 shares of the company’s stock worth $167,000 after buying an additional 6,025 shares during the period.

Insiders Place Their Bets

In other news, insider Christine Ring sold 1,596 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $17.01, for a total transaction of $27,147.96. Following the completion of the sale, the insider now owns 19,838 shares in the company, valued at approximately $337,444.38. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Houte Hans Van sold 2,490 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $51,468.30. Following the completion of the transaction, the chief financial officer now owns 54,479 shares in the company, valued at $1,126,080.93. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Christine Ring sold 1,596 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $17.01, for a total transaction of $27,147.96. Following the sale, the insider now owns 19,838 shares in the company, valued at $337,444.38. The disclosure for this sale can be found here. In the last three months, insiders sold 15,554 shares of company stock valued at $308,044. 7.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on NRIX shares. Needham & Company LLC cut their target price on shares of Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, July 12th. Stephens initiated coverage on Nurix Therapeutics in a report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price target for the company. Piper Sandler restated an “overweight” rating and issued a $35.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. Royal Bank of Canada upped their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday, July 12th. Finally, HC Wainwright lifted their target price on Nurix Therapeutics from $19.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, June 18th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $26.67.

Nurix Therapeutics Trading Up 5.3 %

NRIX opened at $21.88 on Thursday. Nurix Therapeutics, Inc. has a 1-year low of $4.22 and a 1-year high of $24.38. The firm has a 50-day moving average price of $19.08 and a two-hundred day moving average price of $14.71. The stock has a market capitalization of $1.41 billion, a PE ratio of -7.49 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The company had revenue of $12.09 million during the quarter, compared to the consensus estimate of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. On average, research analysts predict that Nurix Therapeutics, Inc. will post -2.78 EPS for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.